Skip to main content

Albireo Pharma, Inc.

ALBODelisted Mar 2, 2023
Industry
Pharmaceutical Preparations
SEC CIK
0001322505

Albireo Pharma, Inc. was delisted on Mar 2, 2023; its insiders filed their last Form 4 on Mar 3, 2023; 96 institutions reported holding it in 13F filings for Q4 2022, worth $401.7M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Albireo Pharma, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Albireo Pharma, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Albireo Pharma, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Chiswell DavidDirector0Mar 3, 20230
Carter Martha J.Chief Regulatory Officer3,654Mar 2, 20230
Scoon DaveyDirector–Mar 2, 20230
Harford Simon N.R.CFO and Treasurer0Mar 2, 20230
Graham MichelleChief Human Resources Officer0Mar 2, 20230
Cooper Ronald Harold WilfredPresident and CEO0Mar 2, 20230
Gutch MichaelDirector–Mar 2, 20230
Mattsson JanChief Scientific Officer0Mar 2, 20230
Dable Habib JDirector–Mar 2, 20230
Streck PaulChief Medical Officer118,966Mar 2, 20230
Hopkinson Craig C.Director10,495Mar 2, 20230
Duncan JasonChief Legal Officer and GC0Mar 2, 20230
Okey StephanieDirector–Mar 2, 20230
Stephenson PamelaChief Commercial Officer0Mar 2, 20230
Alesina SusanDirector–Mar 2, 20230
Edelman Joseph10% Owner1,939,723IndirectOct 13, 20220
Perceptive Advisors LLC10% Owner1,939,723IndirectOct 13, 20220
Perceptive Life Sciences Master Fund Ltd10% Owner1,939,723IndirectOct 13, 20220
Horn Patrick TaylorChief Medical Officer12,355Oct 25, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jan 20, 2023 (view filing)Jan 191 dayStephenson PamelaChief Commercial OfficerSSale−1.77K$43.90−$77.9K−4.0%42.9K after
Jan 23, 2023 (view filing)Jan 23Same dayCarter Martha J.Chief Regulatory OfficerSSale−120$43.80−$5.26K−0.8%14.5K after
Jan 23, 2023 (view filing)Jan 23Same dayCooper Ronald Harold WilfredPresident and CEOSSale−1.06K$43.80−$46.3K−1.8%57.4K after
Jan 23, 2023 (view filing)Jan 23Same dayDuncan JasonChief Legal Officer and GCSSale−228$43.80−$9.99K−1.6%14.1K after
Jan 23, 2023 (view filing)Jan 23Same dayHarford Simon N.R.CFO and TreasurerSSale−102$43.80−$4.47K−0.3%32.7K after
Jan 23, 2023 (view filing)Jan 23Same dayMattsson JanChief Scientific OfficerSSale−197$43.80−$8.63K−0.4%54.5K after
Jan 23, 2023 (view filing)Jan 23Same dayGraham MichelleChief Human Resources OfficerSSale−102$43.80−$4.47K−0.4%24.5K after
Jan 23, 2023 (view filing)Jan 23Same dayStephenson PamelaChief Commercial OfficerSSale−102$43.80−$4.47K−0.2%42.8K after